Last updated on July 2018

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery


Brief description of study

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 [DTPA (BOOSTRIX)-047] and having received the full primary vaccination series as per protocol requirement in study 201330 [DTPA (BOOSTRIX)-048.

Clinical Study Identifier: NCT02853929

Contact Investigators or Research Sites near you

Start Over

US GSK Clinical Trials Call ...

GSK Investigational Site
Carlton, Australia

US GSK Clinical Trials Call ...

GSK Investigational Site
Calgary, AB Canada

US GSK Clinical Trials Call ...

GSK Investigational Site
Halifax, NS Canada

US GSK Clinical Trials Call ...

GSK Investigational Site
Montreal, QC Canada

US GSK Clinical Trials Call ...

GSK Investigational Site
Brno, Czechia

US GSK Clinical Trials Call ...

GSK Investigational Site
Hradec Kralove, Czechia

US GSK Clinical Trials Call ...

GSK Investigational Site
Ostrava - Vitkovice, Czechia

US GSK Clinical Trials Call ...

GSK Investigational Site
Praha, Czechia

US GSK Clinical Trials Call ...

GSK Investigational Site
Aravaca, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Burgos, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Madrid, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Majadahonda (Madrid), Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Santiago de Compostela, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Sevilla, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Praha 4, Czechia

US GSK Clinical Trials Call ...

GSK Investigational Site
Kokkola, Finland

US GSK Clinical Trials Call ...

GSK Investigational Site
Oulu, Finland

US GSK Clinical Trials Call ...

GSK Investigational Site
Seinajoki, Finland

US GSK Clinical Trials Call ...

GSK Investigational Site
Tampere, Finland

US GSK Clinical Trials Call ...

GSK Investigational Site
Turku, Finland

US GSK Clinical Trials Call ...

GSK Investigational Site
Milano, Italy

US GSK Clinical Trials Call ...

GSK Investigational Site
Novara, Italy

US GSK Clinical Trials Call ...

GSK Investigational Site
Málaga, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Antequera/Málaga, Spain

US GSK Clinical Trials Call ...

GSK Investigational Site
Móstoles, Spain